These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35663154)

  • 1. Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study.
    Nagy G; Géher P; Tamási L; Drescher E; Keszthelyi P; Pulai J; Czirják L; Szekanecz Z; Kiss G; Kovács L
    Rheumatol Adv Pract; 2022; 6(2):rkac038. PubMed ID: 35663154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
    Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study.
    Isaacs JD; Salih A; Sheeran T; Patel YI; Douglas K; McKay ND; Naisbett-Groet B; Choy E
    Rheumatol Adv Pract; 2019; 3(1):rkz010. PubMed ID: 31431998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
    Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
    Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
    Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
    Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
    Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
    Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
    Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
    Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
    Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
    Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
    Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
    Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.
    Yazici A; Özdemir Işık Ö; Dalkılıç E; Koca SS; Pehlivan Y; Şenel S; Inanc N; Akar S; Yılmaz S; Soysal Gündüz Ö; Cefle A; Karakaş ÖF; Onen F
    Sci Rep; 2022 Dec; 12(1):21972. PubMed ID: 36539458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting.
    Marsal Barril S; Martin-Martinez MA; Blanco-Garcia FJ; Fernández-Nebro A; García de Vicuña R; Tornero-Molina J; Sánchez-Alonso F; Novella-Navarro M; Escudero-Contreras A; Alegre-Sancho JJ; Urruticoechea-Arana A; Bustabad-Reyes MS; Trenor-Larraz P; Pérez-Sandoval T; Tevar-Sánchez MI; Sánchez-Costa JT; Raya-Álvarez E
    Reumatol Clin (Engl Ed); 2022 Dec; 18(10):567-573. PubMed ID: 36435554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
    Huizinga TW; Conaghan PG; Martin-Mola E; Schett G; Amital H; Xavier RM; Troum O; Aassi M; Bernasconi C; Dougados M
    Ann Rheum Dis; 2015 Jan; 74(1):35-43. PubMed ID: 25169728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.
    Choy E; Caporali R; Xavier R; Fautrel B; Sanmarti R; Bao M; Bernasconi C; Pethö-Schramm A
    Rheumatology (Oxford); 2018 Mar; 57(3):499-507. PubMed ID: 29244149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
    Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
    Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.